Skip to main content
Chengdu Olymvax Biopharmaceuticals Inc. logo

Chengdu Olymvax Biopharmaceuticals Inc. — Investor Relations & Filings

Ticker · 688319 ISIN · CNE1000051H8 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 509 across all filing types
Latest filing 2026-05-25 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688319

About Chengdu Olymvax Biopharmaceuticals Inc.

https://en.olymvax.com/

Chengdu Olymvax Biopharmaceuticals Inc. focuses on the research, development, production, and commercialization of human vaccines. The company develops innovative products to prevent infectious diseases, utilizing advanced technology platforms such as polysaccharide-protein conjugation. Its portfolio includes a Haemophilus influenzae type b (Hib) conjugate vaccine and an adsorbed tetanus vaccine. A key highlight of its research pipeline is the development of a Group A streptococcus vaccine, designed to address significant global health needs. The organization manages the complete lifecycle of its products, from initial laboratory discovery and clinical trials to large-scale manufacturing and distribution. By prioritizing high-quality standards and technological innovation, the company aims to provide effective immunization solutions for diverse populations.

Recent filings

Filing Released Lang Actions
成都欧林生物科技股份有限公司持股5%以上股东减持计划时间届满暨未减持股份的结果公告
Major Shareholding Notification Classification · 90% confidence The document is an announcement that a 5%+ shareholder (泰昌集团) did not reduce any shares under its previously announced share reduction plan. It reports changes (or lack thereof) in a significant shareholding stake. This fits the category for notifications of changes in major shareholdings (MRQ).
2026-05-25 Chinese
成都欧林生物科技股份有限公司2025年度独立董事述职报告（鞠佃文）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by an independent director of the company. It details the director's background, attendance at meetings, participation in committees, communication with auditors, and oversight activities during the year. The content focuses on the director's duties, governance, and compliance with laws and company bylaws. It does not contain financial statements or detailed financial performance data, nor is it a general management discussion or earnings release. It is a specialized report related to board/management information, specifically the independent director's report on their annual duties and governance oversight. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 3555 characters, which is consistent with a detailed report but not a full annual report or financial statement.
2026-03-30 Chinese
成都欧林生物科技股份有限公司关于2025年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Chengdu Olin Biological Technology Co., Ltd. regarding the provision for asset impairment for the fiscal year 2025. It details the impairment losses recognized, the accounting methods used, and the impact on the company's financial results. The announcement states that the impairment provision has been audited and will be disclosed in the 2025 annual report. The document is relatively short (1748 characters) and serves as a formal disclosure of a specific accounting event rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a regulatory announcement about a specific accounting provision. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2026-03-30 Chinese
成都欧林生物科技股份有限公司2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising (募集资金) activities, including the amount raised, management, storage, and actual usage of the funds for the fiscal year 2025. It includes specific financial figures, regulatory approvals, and auditor and sponsor opinions on the proper use of the funds. The document is titled as a "专项报告" (special report) on fundraising funds storage, management, and actual usage, which aligns with a capital/financing update rather than a full annual report or earnings release. It is not a brief announcement but a substantive report with financial data and regulatory compliance details. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-03-30 Chinese
成都欧林生物科技股份有限公司2025年度审计报告
Audit Report / Information Classification · 93% confidence The document is titled “审计报告” and issued by 中勤万信会计师事务所, containing the auditor’s opinion, basis of audit, key audit matters, auditor and management responsibilities, followed by the audited consolidated and parent company financial statements. It is a standalone audit report, not a full annual report or mere announcement. This corresponds to the Audit Report / Information category. FY 2025
2026-03-30 Chinese
成都欧林生物科技股份有限公司2025年独立董事述职报告（届满离任-王乔）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Chengdu Olin Biotechnology Co., Ltd. covering the director's duties, attendance, and activities during the 2025 term. It includes information on governance, committee participation, communication with auditors, and evaluation of company practices. The content focuses on the director's role and governance oversight rather than financial results or audit opinions. It is not an annual report, audit report, or financial statement. It is a specific report related to board/management information, particularly the independent director's performance and governance role. Therefore, the document fits best under Board/Management Information (MANG). The document length is 3119 characters, which is consistent with a detailed management or board report rather than a brief announcement or regulatory filing.
2026-03-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.